Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Definium Therapeutics ( (DFTX) ) has shared an update.
On April 22, 2026, Definium Therapeutics used its Investor and Analyst Day to spotlight clinical progress and a patient-centric commercial strategy for DT120 ODT in major depressive disorder and generalized anxiety disorder. The company emphasized DT120 ODT as a potential multi-billion-dollar opportunity, underpinned by a differentiated psychedelic formulation intended for scalable use across care settings and backed by IP protections.
Definium reported that its Phase 3 Emerge trial in major depressive disorder is fully enrolled with topline data expected in late second-quarter 2026, while the Ascend trial has sites activated and plans first patient dosing in the second quarter of 2026. In generalized anxiety disorder, the Phase 3 Voyage study has completed enrollment with a 214-patient cohort targeting an early third-quarter 2026 readout, and the Panorama trial has completed blinded sample size re-estimation, closed screening above its 200-patient target, and now guides to a late third-quarter 2026 topline.
The company also expanded its DT120 ODT franchise into posttraumatic stress disorder, outlining plans to initiate the Phase 3 Haven study in 2027 with approximately 200 participants and a primary CAPS-5 endpoint at week eight. Together, the three near-term pivotal readouts over the next six months and the planned PTSD program are positioned as key value inflection points that will shape Definium’s regulatory strategy, support potential NDA pathways, and influence its standing in the emerging psychedelic psychiatry market.
The most recent analyst rating on (DFTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Definium Therapeutics stock, see the DFTX Stock Forecast page.
Spark’s Take on DFTX Stock
According to Spark, TipRanks’ AI Analyst, DFTX is a Neutral.
Score is driven by weak financial performance from ongoing losses and accelerating cash burn, partially cushioned by a low-debt balance sheet and strong liquidity outlook cited on the earnings call. Technicals are supportive with a clear uptrend, but momentum is overextended. Valuation provides limited support given negative earnings and no dividend.
To see Spark’s full report on DFTX stock, click here.
More about Definium Therapeutics
Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing a new generation of therapeutics aimed at the underlying causes of psychiatric and neurological disorders. Headquartered in New York and listed on Nasdaq under the symbol DFTX, the company is building a psychiatry-focused franchise around DT120 ODT, a proprietary fast-dissolve lysergide tartrate (LSD) formulation for conditions including major depressive disorder, generalized anxiety disorder, and posttraumatic stress disorder, supported by a multi-layered intellectual property strategy.
Average Trading Volume: 1,756,589
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.31B
See more insights into DFTX stock on TipRanks’ Stock Analysis page.